| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.066 | 0.4 |